A Study of LY2216684 in Participants With Major Depression Disorder
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Major Depressive Disorder
Related studies linked through entity extraction aliases.
Electroencephalography (EEG) Signal Processing
- Status
- UNKNOWN
- Phase
- N/A
Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)
- Status
- COMPLETED
- Phase
- N/A
Neurophysiologic Monitoring of Antidepressant Treatment
- Status
- COMPLETED
- Phase
- PHASE4
The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope
- Status
- UNKNOWN
- Phase
- PHASE4
The Study of Serum Melatonin Rhythm Levels in Patients With Major Depressive Disorder
- Status
- COMPLETED
- Phase
- N/A
Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
- Status
- COMPLETED
- Phase
- PHASE3
Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
- Status
- TERMINATED
- Phase
- N/A
A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)
- Status
- COMPLETED
- Phase
- N/A
African American Depression Intervention Trial (AADI)
- Status
- COMPLETED
- Phase
- PHASE3
Pioglitazone and Quetiapine XR Pharmacogenetic Study
- Status
- COMPLETED
- Phase
- N/A
PHARMO Institute Seroquel Safety Study
- Status
- COMPLETED
- Phase
- N/A
Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder
- Status
- TERMINATED
- Phase
- PHASE4
Deficits in Emotion Regulation Skills as a Maintaining Factor in Major Depressive Disorder
- Status
- COMPLETED
- Phase
- NA
Internet-Based Depression Screening for College Students
- Status
- COMPLETED
- Phase
- NA
Efficacy and Safety of Cranial Electrical Stimulation (CES) for Major Depressive Disorder (MDD)
- Status
- COMPLETED
- Phase
- NA
Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
- Status
- COMPLETED
- Phase
- PHASE3
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
- Status
- COMPLETED
- Phase
- PHASE3
Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features
- Status
- TERMINATED
- Phase
- N/A